RxDoctor Payments Data

Jerzy Kornilow

Optometrist · Boonsboro, MDNPI 1275507956

Payments from drug & device makers

$690in general payments, 2019–2025

Across 27 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$300
  • Apellis Pharmaceuticals, Inc.$125
  • Kala Pharmaceuticals, Inc.$59
  • Novartis$53
  • LKC Technologies, Inc.$45
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$44
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690 in reported general payments places this provider in the 45th percentile of 790 optometrist providers in Maryland.

See all optometrist providers in Maryland

Medicare billing

Part B allowed, 2024
$264,302
Medicare patients
1,071
Services billed
3,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost94$59,062
RestasisCyclosporine22$30,223
CequaCyclosporine12$14,028
RhopressaNetarsudil Mesylate21$12,151
SimbrinzaBrinzolamide/Brimonidine Tart20$9,469
Cyclosporine11$8,754
Latanoprost396$8,387
Travoprost11$5,674
Loteprednol Etabonate15$4,950
TobradexTobramycin/Dexamethasone16$4,203
Tobramycin-DexamethasoneTobramycin/Dexamethasone86$3,060
Epinastine Hcl38$2,875
Bromfenac Sodium14$2,464
Brimonidine Tartrate91$2,289
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$1,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sun Pharmaceutical Industries Inc.Cequa$300$14,02812 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$44$4,95015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 790 optometrist providers in Maryland.

Other optometrist in Boonsboro

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →